Last mentioned: Feb 25, 2026
Institutional Exit Revealed
13F filings reveal a $170 million divestment by a major institutional fund.
Institutional Exit
SEC filings reveal a $170 million position liquidation by a major fund.
120% Gain Milestone
PTGX stock reaches a 120% gain milestone from its 52-week low.
J&J Partnership Milestone
Johnson & Johnson advances JNJ-2113 into late-stage trials, validating oral peptide tech.
120% Rally
Stock price reaches a 12-month peak following sustained clinical momentum.
Phase 3 Data Release
Positive Phase 3 data for rusfertide in polycythemia vera triggers initial stock rally.
J&J Partnership Expansion
Johnson & Johnson expands the scope of the oral peptide collaboration.
Phase 2 Success
JNJ-2113 reports positive Phase 2 data in plaque psoriasis, triggering milestone payments.
Protagonist Therapeutics has seen its stock price more than double following clinical breakthroughs in its oral peptide portfolio, yet a major institutional investor has liquidated a $170 million position. This tactical exit highlights the tension between clinical optimism and institutional profit-taking as the company nears critical Phase 3 milestones.
Protagonist Therapeutics shares have soared 120% following clinical and regulatory milestones, but a recent $170 million institutional exit is raising questions about the stock's near-term ceiling. The move highlights a growing divergence between retail momentum and institutional profit-taking in the biotech sector.